CohBar, Inc. (CWBR)

NASDAQ: CWBR · IEX Real-Time Price · USD
2.62
+0.07 (2.75%)
At close: Feb 7, 2023, 3:59 PM
2.63
+0.01 (0.38%)
After-hours: Feb 7, 2023, 4:17 PM EST
2.75%
Market Cap 7.62M
Revenue (ttm) n/a
Net Income (ttm) -11.17M
Shares Out 2.91M
EPS (ttm) -3.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,765
Open 2.58
Previous Close 2.55
Day's Range 2.56 - 2.71
52-Week Range 1.50 - 10.50
Beta 1.90
Analysts Sell
Price Target 18.36 (+600.76%)
Earnings Date Mar 27, 2023

About CWBR

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 9
Stock Exchange NASDAQ
Ticker Symbol CWBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CWBR stock is "Sell." The 12-month stock price forecast is $18.36, which is an increase of 600.76% from the latest price.

Price Target
$18.36
(600.76% upside)
Analyst Consensus: Sell
Stock Forecasts

News

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 Conference call and webcast today at 5:00 p.m. ET, November 8, 2022

3 months ago - GlobeNewsWire

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

3 months ago - GlobeNewsWire

Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 months ago - Zacks Investment Research

7 Nasdaq Stocks to Sell Before They Die

As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500...

Other symbols: AURBYNDCLOVMTTRMULN
4 months ago - InvestorPlace

CohBar Announces Reverse Stock Split

MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its geno...

4 months ago - GlobeNewsWire

CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference

MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its geno...

5 months ago - GlobeNewsWire

CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

IND for CB5138-3 on track for second half of 2023

6 months ago - GlobeNewsWire

CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

6 months ago - GlobeNewsWire

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genom...

7 months ago - GlobeNewsWire

CohBar to Participate at Upcoming Conferences in June 2022

MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genom...

8 months ago - GlobeNewsWire

CohBar to Present at the H.C. Wainwright Global Investment Conference

MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome...

9 months ago - GlobeNewsWire

CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Conference call and webcast today at 5:00 p.m. ET, May 16, 2022 Conference call and webcast today at 5:00 p.m. ET, May 16, 2022

9 months ago - GlobeNewsWire

CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal

MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encod...

9 months ago - GlobeNewsWire

CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

10 months ago - GlobeNewsWire

CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Conference call and webcast at 5:00 p.m. ET today, March 29, 2022 Conference call and webcast at 5:00 p.m. ET today, March 29, 2022

11 months ago - GlobeNewsWire

CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

11 months ago - GlobeNewsWire

CohBar to Present at H.C. Wainwright BIOCONNECT Conference

MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genom...

1 year ago - GlobeNewsWire

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

1 year ago - InvestorPlace

CohBar Announces Changes to its Board of Directors and R&D Leadership

Founding board members transition to reconstituted Scientific Advisory Board

1 year ago - GlobeNewsWire

CohBar's CEO to Participate in Upcoming BIO Webinar

MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

1 year ago - GlobeNewsWire

7 Penny Stocks With the Potential to 10X in 2022

The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appea...

Other symbols: CBAYPAYSSENSSOLOSRGA
1 year ago - InvestorPlace

CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update

Company to host conference call at 5:00 p.m. ET

1 year ago - GlobeNewsWire

CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021

Company to host conference call at 5:00 p.m. ET Company to host conference call at 5:00 p.m. ET

1 year ago - GlobeNewsWire

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

1 year ago - GlobeNewsWire

CohBar Announces Proposed Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

1 year ago - GlobeNewsWire